Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | STK17B | O94768 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 3/20 | 0.32 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654635 | 1.00 | MEN1 (0.35) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL7649928 | 1.00 | MEN1 (0.35) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL16382613 | 1.00 | MEN1 (0.35) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL22057240 | 1.00 | MEN1 (0.35) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL31738409 | 1.00 | MEN1 (0.35) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL16378826 | 0.85 | KDM4E (0.34) | STK17BKDM4EMAPK1ATMACHE | |
| SCHEMBL18924580 | 0.83 | KDM4E (0.33) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL7170811 | 0.82 | MEN1 (0.48) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL5196943 | 0.81 | TYMS (0.40) | MEN1KMT2ASTK17BKDM4EMAPK1 | |
| SCHEMBL5196941 | 0.81 | TYMS (0.40) | MEN1KMT2ASTK17BKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670171-B2 | Process for preparing fluoxastrobin | ARYSTA LIFESCIENCE CORP (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670171-B2 | Process for preparing fluoxastrobin | ARYSTA LIFESCIENCE CORP (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORP (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORP (JP) | 2016-08-18 | — | — | US | disclosed |
| US-9193698-B2 | Process for preparing fluoxastrobin | ADVINUS THERAPEUTICS, LTD. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-9193698-B2 | Process for preparing fluoxastrobin | ADVINUS THERAPEUTICS, LTD. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| US-6462193-B1 | ADDING 3-AZIDO-2-HYDROXYPROPANALDEHYDE WITH DIHYDROXYACETONE PHOSPHATE USING AN ALDOLASE, HYDROLYZING THE INTERMEDIATE WITH ACID PHOSPHATASE, ISOMERIZING USING AN ISOMERASE, CYCLIZING USING REDUCTIVE AMINATION TO PRODUCE TETRAHYDROXYAZEPINE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
| US-6462205-B1 | E ISOMERS ARE FORMED PREDOMINANTLY IN HIGH YIELDS | BAYER AKTIENGESELLSCAHFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1165539-A1 | METHOD OF PREPARING BENZOFURANDIONE OXIME DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058299-A1 | METHOD OF PREPARING BENZOFURANDIONE OXIME DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | MEN1 3840/4885KMT2A 2793/4885STK17B 4531/4885 |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | MEN1 3840/4885KMT2A 2793/4885STK17B 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.